COMPANY PROFILE

Swedish Orphan Biovitrum

Explore full profile

Engages in the development, marketing, and distribution of orphan products and specialty pharmaceuticals

Solna kommun, SwedenFounded 1988Biotech & Life Sciences

Valuation $20B Market cap · 2026

Revenue $4.01B Latest reported FY

EBITDA $1.54B Latest reported FY

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum, commonly known as Sobi, emerged in 2010 from the strategic merger of two pioneering entities in the pharmaceutical industry: Swedish Orphan International and Biovitrum. Swedish Orphan International, founded in 1988, was a trailblazer in the development of orphan drugs, which are medications intended for the treatment of rare diseases. Biovitrum, on the other hand, was established in 2001 following the merger of several units of Pharmacia, now part of Pfizer, and was spun off to a consortium of investors led by Nordic Capital and MPM Capital Funds.

The merger was a significant event in the pharmaceutical landscape, combining Swedish Orphan's expertise in rare diseases with Biovitrum's strong biotechnological capabilities. This union aimed to create a robust platform for developing and delivering innovative therapies for patients with rare and debilitating diseases, focusing on areas such as hematology, immunology, and specialty care.

Since its formation, Sobi has continued to expand its reach and impact through strategic collaborations and partnerships with major pharmaceutical companies like Sanofi and Apellis Pharmaceuticals. These alliances have been crucial in enhancing Sobi's research and development capabilities, allowing the company to bring more life-changing therapies to market.

Today, Sobi stands as a testament to the power of strategic mergers and collaborations in the pharmaceutical industry, dedicated to improving the lives of patients with rare diseases worldwide.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 1988
Headquarters: Solna kommun, Sweden
Listing: IPO 2006
Employees: 2,423
Open positions: None listed
Dealroom signal: 52.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Risk Management, Biotechnology, Drug Development, Genetics and genomics, Horizon Europe, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b, b2c
Investment activity: 7 companies, latest Aug 2026
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO DEBT✓Debt	May 2024	$363M	—	Undisclosed	↗
POST IPO DEBT✓Debt	May 2023	$0	—	Bank of America · Danske Bank	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$4B	+17.3%	$1.5B	38.4%	$793M	19.8%	$401M
2025	$3.4B	+8.5%	$2.9B	85.7%	$58M	1.7%	$401M
2024	$3.1B	+17.6%	$1.1B	35.7%	$470M	14.9%	$428M
2023	$2.7B	+17.7%	$876M	32.7%			$338M
2022	$2.3B	+21%	$750M	33%
2021	$1.9B	+1.8%	$699M	37.2%
2020	$1.8B	—	$762M	41.3%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Swedish Orphan Biovitrum website traffic

Latest recorded traffic for Swedish Orphan Biovitrum is 76K monthly website visits, up 322.2% over the last three months. Swedish Orphan Biovitrum's team grew 55.8% over the past year.

Latest monthly visits76K 3-month web change+322.2% 1-year team growth+55.8%

Monthly website visitsApr 2016–Feb 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TOToxysProvides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development	Leiden, Netherlands	Operational	41	$2.2M	$8.8M
ALAllelicaSoftware as a Service that allows clinical genetics lab to perform Polygenic Risk Score analysis	San Francisco, United States	Operational
GEGenialisCloud software for the visual exploration of next generation sequencing data	Boston, United States	Operational
STSenolytic TherapeuticsA discovery-stage biotech developing novel medicines that target senescent cells	Barcelona, Spain	Closed
FMFoundation MedicineTransformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease	Boston, United States	Acquired
ATArctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics	Reykjavík, Iceland	Operational
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational
OBOchre BioDevelops RNA therapies for chronic liver diseases, a leading cause of death globally	Oxford, United Kingdom	Operational